HilleVax, Inc.
HilleVax, Inc. (HLVX): 2 pipeline candidates · ~591 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
590.5 months
D/E 0.18 · 0% dilution
Lead: Phase 2/Phase 3
2 candidates
N/A
N/A
A transparent, data-derived signal for HilleVax, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$58.7M
Quarterly Burn
$789K
Runway
590.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in HilleVax, Inc.'s pipeline?
HilleVax, Inc. (HLVX) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is HilleVax, Inc.'s lead drug candidate?
HilleVax, Inc.'s most advanced tracked candidate is hil-214 (Phase 2) for Gastroenteritis.
What is HilleVax, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, HilleVax, Inc. has approximately 590.5 months of cash runway.
Who is the CEO of HilleVax, Inc.?
Harrison Avenue Boston is the chief executive officer of HilleVax, Inc. (HLVX).
Get the full picture on HilleVax, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.